Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer (Targeted Oncology, (2020), 15, 2, (163-174), 10.1007/s11523-020-00714-0)

Ramesh K. Ramanathan; Daniel D. Von Hoff; Ferry Eskens; George Blumenschein; Donald Richards; Isabelle Genvresse; Susanne Reschke; Camille Granvil; Adam Skubala; Carol Peña; Klaus Mross

doi:10.1007/s11523-020-00762-6

Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer (Targeted Oncology, (2020), 15, 2, (163-174), 10.1007/s11523-020-00714-0)

Ramesh K. Ramanathan, Daniel D. Von Hoff, Ferry Eskens, George Blumenschein, Donald Richards, Isabelle Genvresse, Susanne Reschke, Camille Granvil, Adam Skubala, Carol Peña, Klaus Mross

Thoracic Head & Neck Medical Oncology

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The article Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer.

Original language	English (US)
Pages (from-to)	803
Number of pages	1
Journal	Targeted oncology
Volume	15
Issue number	6
DOIs	https://doi.org/10.1007/s11523-020-00762-6
State	Published - Dec 2020

ASJC Scopus subject areas

Oncology
Cancer Research
Pharmacology (medical)

Access to Document

10.1007/s11523-020-00762-6

Fingerprint

Dive into the research topics of 'Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer (Targeted Oncology, (2020), 15, 2, (163-174), 10.1007/s11523-020-00714-0)'. Together they form a unique fingerprint.

Cite this

Ramanathan, R. K., Von Hoff, D. D., Eskens, F., Blumenschein, G., Richards, D., Genvresse, I., Reschke, S., Granvil, C., Skubala, A., Peña, C., & Mross, K. (2020). Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer (Targeted Oncology, (2020), 15, 2, (163-174), 10.1007/s11523-020-00714-0). Targeted oncology, 15(6), 803. https://doi.org/10.1007/s11523-020-00762-6

Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer (Targeted Oncology, (2020), 15, 2, (163-174), 10.1007/s11523-020-00714-0). / Ramanathan, Ramesh K.; Von Hoff, Daniel D.; Eskens, Ferry et al.
In: Targeted oncology, Vol. 15, No. 6, 12.2020, p. 803.

Research output: Contribution to journal › Comment/debate › peer-review

Ramanathan, RK, Von Hoff, DD, Eskens, F, Blumenschein, G, Richards, D, Genvresse, I, Reschke, S, Granvil, C, Skubala, A, Peña, C & Mross, K 2020, 'Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer (Targeted Oncology, (2020), 15, 2, (163-174), 10.1007/s11523-020-00714-0)', Targeted oncology, vol. 15, no. 6, pp. 803. https://doi.org/10.1007/s11523-020-00762-6

Ramanathan RK, Von Hoff DD, Eskens F, Blumenschein G, Richards D, Genvresse I et al. Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer (Targeted Oncology, (2020), 15, 2, (163-174), 10.1007/s11523-020-00714-0). Targeted oncology. 2020 Dec;15(6):803. doi: 10.1007/s11523-020-00762-6

@article{0eb8c489ac7745f8a61068bc4818027f,

title = "Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer (Targeted Oncology, (2020), 15, 2, (163-174), 10.1007/s11523-020-00714-0)",

abstract = "The article Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer.",

author = "Ramanathan, {Ramesh K.} and {Von Hoff}, {Daniel D.} and Ferry Eskens and George Blumenschein and Donald Richards and Isabelle Genvresse and Susanne Reschke and Camille Granvil and Adam Skubala and Carol Pe{\~n}a and Klaus Mross",

note = "Publisher Copyright: {\textcopyright} 2020, The Author(s).",

year = "2020",

month = dec,

doi = "10.1007/s11523-020-00762-6",

language = "English (US)",

volume = "15",

pages = "803",

journal = "Targeted oncology",

issn = "1776-2596",

publisher = "Springer Paris",

number = "6",

}

TY - JOUR

T1 - Correction to

T2 - Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer (Targeted Oncology, (2020), 15, 2, (163-174), 10.1007/s11523-020-00714-0)

AU - Ramanathan, Ramesh K.

AU - Von Hoff, Daniel D.

AU - Eskens, Ferry

AU - Blumenschein, George

AU - Richards, Donald

AU - Genvresse, Isabelle

AU - Reschke, Susanne

AU - Granvil, Camille

AU - Skubala, Adam

AU - Peña, Carol

AU - Mross, Klaus

PY - 2020/12

Y1 - 2020/12

N2 - The article Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer.

AB - The article Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer.

UR - http://www.scopus.com/inward/record.url?scp=85094118280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85094118280&partnerID=8YFLogxK

U2 - 10.1007/s11523-020-00762-6

DO - 10.1007/s11523-020-00762-6

M3 - Comment/debate

C2 - 33108585

AN - SCOPUS:85094118280

SN - 1776-2596

VL - 15

SP - 803

JO - Targeted oncology

JF - Targeted oncology

IS - 6

ER -

Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer (Targeted Oncology, (2020), 15, 2, (163-174), 10.1007/s11523-020-00714-0)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this